NuVasive(R) Announces First Patients in Japan Treated With Precept(R) Posterior Fixation System

Marketwired
NuVasive(R) Announces First Patients in Japan Treated With Precept(R) Posterior Fixation System
.

View photo

The Precept® posterior fixation system offers the most advanced technologies in guide design, rod insertion, …

SAN DIEGO, CA--(Marketwired - Sep 26, 2013) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the first surgeries were performed in Japan using the Precept® posterior fixation system.

On July 31, 2013, NuVasive received regulatory Shonin approval for Precept products, opening the door for the Company to offer a minimally disruptive posterior fixation solution to patients and surgeons in Japan. The approval furthers the Company's ability to participate in the world's second largest spine market, where the eXtreme Lateral Interbody Fusion (XLIF®) approach and other posterior products were previously approved. The Precept Posterior Fixation System provides surgeons with unprecedented ability to treat a wide range of pathologies, all while offering an unparalleled ease of use.

Surgeon proctors, who will instruct upcoming Precept training courses, have started to schedule surgeries now that the new system is available. 

"We have our sights set on changing spine surgery and improving patient outcomes in Japan, an exciting new market for us," said Alex Lukianov, NuVasive Chairman and Chief Executive Officer. "With the approval and launch of Precept, we can introduce Japanese surgeons to additional innovation within our comprehensive portfolio of procedurally integrated spine solutions." 

Russell Powers, NuVasive Executive Vice President of International, said, "We are absolutely thrilled to offer Precept in Japan, which will advance our strategy of driving the shift toward minimally disruptive approaches globally. Precept is a highly differentiated solution with advanced guide technology, superior rod insertion options, and multiple reduction capabilities. The initial reception in Japan has been fantastic, and I applaud all of the NuVasive teams who worked diligently to achieve this milestone."

The NuVasive Japan office officially opened in April 2013 in Tokyo, Japan. The office is headed by NuVasive Executive Vice President of Asia Pacific, Takaaki Tanaka. Tanaka-san has been with the Company since 2009, and brings an extensive 20 years of experience in the spine industry.

About Precept®
The Precept system offers the most advanced technologies in guide design, rod insertion, set screw delivery, and multiple reduction capabilities. Elegant yet powerful reduction options, impressive compression/distraction systems, and efficient instrumentation result in a system designed to address simple to the most complex pathologies.

About NuVasive®

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons worldwide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.  

Contact:
Investor
Tina Jacobsen
NuVasive, Inc.
858-320-5215
Email Contact

Media
Nicole Collins
NuVasive, Inc.
858-909-1907
Email Contact
View Comments (0)